BioVaxys Technology Corp. BVAXF

Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > News BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding

<< Previous

Bullboard Posts

Next >>

Comment by Humaniston Feb 16, 2022 1:38pm

77 Views

Post# 34434527

RE:RE:RE:News BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding

Hi frankman, i am still holding as well, but my avg is much higher, what's your best guess for the low financing btw?
i like the idea its shlumberger not a small unknown company, it gives me abit of confidence

frankman wrote: Hi Humanist If you remember I told you about TCF over a year ago. I still have shares. Many are going to be shocked by the low Trillion financing. Art is still pumping the stock. And I told him not to wait too long as he has over a year now.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec